Smoking, race, ancestry and prospective abstinence

Andrew W Bergen PhD^{a,b,*}, Carolyn M Ervin PhD^b, Christopher S McMahan PhD^c, James W Baurley PhD^b, Harold S Javitz PhD^d, Sharon Hall PhD^e

^aOregon Research Institute, Eugene, OR

^bBioRealm, LLC, Walnut, CA

^cSchool of Mathematical and Statistical Sciences, Clemson University, Clemson, SC

^dEducation Division, SRI International, Menlo Park, CA

^eDepartment of Psychiatry and Behavioral Sciences, University of California San Francisco Weill Institute for Neurosciences, San Francisco, CA

Word count = 3193, Table count=4

*Corresponding author

Email address: abergen@ori.org (Andrew W Bergen PhD)

Abstract

Background: Factors influencing cessation include biopsychosocial characteristics, treatments and responses to treatment. The first cessation trial designed to assess cessation disparities between African American and White cigarette smokers demonstrated that socioeconomic, treatment, psychosocial and smoking characteristics explained cessation disparities. Ongoing translational efforts in precision cessation treatment grounded in genetically informed biomarkers have identified cessation differences by genotype, metabolism, ancestry and treatment.

Methods: In planned analyses, we evaluated six smoking-related measures, demographic and socioeconomic covariates, and prospective abstinence (7-day point prevalence at 12 weeks with bupropion, nicotine replacement and counseling treatments). We assessed concurrent and predictive validity in two covariate models differing by inclusion of Office of Management and Budget (OMB) race/ethnicity or genomic ancestry.

Results: We studied Pharmacogenetic Study participants (N=456, mean age 49.5 years, 41.5% female, 7.4% African American, 9.4% Multiracial, 6.5% Other, and 6.7% Hispanic). Cigarettes per day (OR=0.95, $P<.001$), Fagerström score (OR=0.89, $P<=.014$), Time-To-First-Cigarette (OR=0.75, $P<=.005$) and predicted urinary nicotine metabolite ratio (OR=0.57, $P<=.039$) were associated with abstinence. OMB African American race (ORs from 0.31 and 0.35, $p\text{-values}<=.007$) and African genomic ancestry (ORs from 0.21 and 0.26, $p\text{-values}<=.004$) were associated in all abstinence models.

Conclusions: Four smoking-related measures exhibited association with abstinence, including predicted nicotine metabolism based on a novel genomic model. African genomic ancestry was independently associated with reduced abstinence. Treatment research that includes social, psychological, treatment and biological factors is needed to reduce cessation disparities.

Keywords: Smoking Cessation, Predicted nicotine biomarker, African Americans

Implications

- This is the first application of a statistical learning model of the urinary nicotine metabolite ratio to cessation. Results are concordant with biochemical and genetic models of the plasma nicotine metabolite ratio in multiethnic samples.
- The urinary ratio exhibits the largest standardized effect size of four smoking-related measures associated with cessation (time-to-first cigarette, total Fagerström score and cigarettes per day were the others).
- The social construct of African American race and genomic African ancestry are significant covariates in all cessation models.
- Results point to social and biological mechanisms requiring investigation in larger samples to understand and reduce cessation health disparities.

INTRODUCTION

Tobacco-attributable disease remains the largest modifiable source of mortality in the United States¹. Numerous tobacco-related health disparities (TRHDs) exist in the United States due to inequities in tobacco related exposures, in social resources supporting healthy behaviors, and in access to health care². Demographic, socioeconomic and health condition TRHDs include greater tobacco-related cancer incidence and mortality in Non-Hispanic Black vs White smokers¹, increased smoking among the less well educated³, and excess smoking and related mortality in those with mental illness⁴. Among efforts to reduce these complex TRHDs, better understanding of the factors and mechanisms underlying cessation disparities will support development of more effective interventions.

Nollen *et al* provided evidence on cessation disparities and explanatory factors between African American and White smokers from planned analyses of the first prospective trial designed to test such differences: "Understanding Disparities in Quitting in African American and White Smokers" (NCT01836276^{5,6}). In $N=448$ Midwestern smokers of modest income stratified by race, age, and gender, Black smokers were significantly less likely than White smokers to be abstinent (7-day point prevalence at the end of a varenicline and counseling intervention, with Intent-To-Treat abstinence OR=0.51 (95% CI 0.32-0.83) $P<.007$, and in completers only, a OR=0.42 (0.26-0.69) $P<.001$)⁶. In preplanned analyses of age, sex, race and factors associated with race and abstinence, they identified home ownership, income, neighborhood problems, study visits completed, and plasma cotinine in a highly predictive best fit joint model (83% concordance with abstinence). They concluded that the best fit model was supported by pathway analyses linking employment and education to cessation through negative affect, across races⁷.

Nollen *et al* identified cessation disparities and explanatory factors in analyses of US smokers in the randomized placebo-controlled trial called "Evaluating Adverse Events in a Global Smoking Cessation Study" (EAGLES, NCT01456936)^{8,9}. EAGLES was designed to test the relative neuropsychiatric risks and efficacy of varenicline and bupropion to those of nicotine replacement therapy (NRT) and placebo; a total of $N=8144$ smokers (≥ 10 cigarettes per day, CPD) with and without psychiatric disorders were enrolled⁹. The primary outcome was continuous abstinence from weeks 9 - 24 (abstinence). Initial analyses demonstrated no significant increase in neuropsychiatric adverse events due to varenicline or bupropion compared to NRT or placebo, or across diagnostic cohorts; greatest effectiveness was observed with varenicline, and with bupropion and NRT *versus* placebo. In analyses of data from $N=4109$ US EAGLES participants (25.9% Black and 74.1% White)⁸, Nollen *et al* examined treatment group, psychiatric cohort, and race stratified groups for association with abstinence, then examined 41 participant and trial characteristics for association with race and with abstinence, and constructed a best joint model of abstinence. They observed reduced abstinence over all treatments and diagnostic cohorts in Black participants when compared to White participants (OR=0.53 (0.41-0.69) $P<.001$). Similar disparities were observed for varenicline and bupropion arms across cohorts, within the psychiatric cohort, but not within the non-psychiatric cohort. From 19 participant and trial characteristics associated with both race and abstinence, the final abstinence model retained six baseline variables (age, race, anxiety, Fagerström Test for Nicotine Dependence (FTND), CPD, and lifetime quit attempts) and three trial variables (study drug discontinuation, depression score change and emergent adverse events). These analyses have provided evidence that the social construct of race, and demographic, psychometric, smoking, socioeconomic and treatment measures are associated with cessation disparities^{8,9}.

Nicotine metabolite biomarkers include the nicotine metabolite ratio (NMR, *trans*-3'-hydroxycotinine/cotinine)¹⁰, which measures metabolism, and total nicotine equivalents (TNE, the

molar sum of nicotine and its principal metabolites including cotinine, COT, and *trans*-3'-hydroxycotinine, 3HC), which measures intake¹¹. The plasma NMR and the urinary NMR are associated with CPD^{12,13}, and TNE is associated with the FTND and its CPD and Time-To-First-Cigarette items¹⁴. The NMR, and another genetically-informed biomarker of variants at the alpha 5 nicotinic acetylcholine receptor gene (*CHRNA5*) associated with CPD, cessation and lung cancer¹⁵⁻¹⁷, are being translated into precision cessation therapy¹⁸. A prospective stratified randomized trial of the NMR and of varenicline, NRT and placebo, with primary abstinence outcome 7-day point prevalence abstinence at end of treatment, identified a NMR-by-treatment interaction (NCT01314001)¹⁹. Normal nicotine metabolizers achieved greater abstinence with varenicline, while slow metabolizers achieved equivalent abstinence with either varenicline or NRT but reported greater adverse events with varenicline, suggesting a treatment strategy for translational research. A prospective stratified randomized trial of the *CHRNA5* biomarker and of varenicline, combined NRT (patch and lozenge) and placebo with primary abstinence outcome 7-day point prevalence abstinence at end of treatment identified a genotype-by-treatment interaction within non-European American (88% African American) participants (NCT02351167)²⁰. Those participants with higher risk genotypes (rs16969968 GA/AA), achieved greater abstinence with varenicline vs placebo, while participants with the low risk genotype (rs16969968 GG) achieved greater abstinence with cNRT vs placebo.

African American and European American cigarette smokers differ in nicotine metabolite and smoking intensity measures; African American smokers exhibit lower levels of CPD, exhaled carbon monoxide (CO), the NMR (plasma and urinary), TNE and plasma COT+3HC, but higher plasma COT and higher nicotine exposures per cigarette²¹⁻²³. Differences in nicotine metabolites were hypothesized to contribute to TRHD²¹. Robust associations of nicotine and toxicants in Black and White smokers²⁴, modeling smoking intensity vs total nicotine equivalents and risk for lung cancer in multiethnic populations²⁵, and increased toxicant exposures in African

American smokers²⁶, support the hypothesis that increased tobacco exposures per cigarette contribute to TRHD.

In this study, we performed planned analyses to evaluate the utility of four self-reported smoking measures (cigarettes per day, CPD; the FTND CPD item, FCPD; time-to-first-cigarette, TTFC; and total FTND score, FTND) and two biomarkers (exhaled carbon monoxide, CO, and predicted urinary nicotine metabolism, uNMR), to predict prospective abstinence in participants recruited from two randomized clinical trials^{27,28}. We assessed association of these six smoking-related measures with demographic, socioeconomic and ancestry covariates, and then with prospective abstinence. We estimated and compared the influence of two covariate models, one containing the social constructs of race and ethnicity and the other, genomic ancestry.

METHODS

Ethical Approval

Written informed consent was obtained from all participants. Research described herein received approvals from the Institutional Review Boards of BioRealm and Oregon Research Institute.

Participants (N=456)

We studied existing clinical and novel genomic data from participants of two randomized smoking cessation trials (RCT NCT00087880²⁸ and RCT NCT00086385²⁷, who provided whole blood and consent for a study called Pharmacogenetics of Bupropion and Nicotine Smoking Cessation Trial (Pharmacogenetic Study)²⁹ (**Table 1**). See **Supplementary Materials** for additional details on the RCTs and Pharmacogenetic Study.

Pharmacogenetic Study Recruitment

This study was initiated when the RCTs were in progress. Thus, cessation trial participants were approached at their first scheduled RCT assessment after the initiation of the present study, and were asked if they would be willing to participate in a study of the genetics of response to smoking cessation treatment with nicotine and bupropion, dependence on tobacco smoking, and nicotine metabolism and clearance. The Pharmacogenetic Study was described, participants read the consent form, were given an opportunity to ask questions, and interested participants signed the consent form. Participants were paid \$50 for providing a blood sample.

Genomic Prediction of Ancestry and uNMR

Pharmacogenetic Study participant DNA was prepared from whole blood (Gentra Puregene, Qiagen, Germantown, MD), and genotyped at Infinite Biologics (Piscataway, NJ). Genotype data was subjected to quality control and genotype analysis.

Ancestry proportions were estimated by extracting genotypes from N=5,516 ancestry informative markers from the Pharmacogenetic Study data. After combining these genotypes with genotypes from 1000 Genomes Project Phase 3 version 5a, fastSTRUCTURE was used with default settings and $k=3$ populations³⁰. Population assignments from the 1000 Genome Project and self-reported race were used to label estimated African, Asian, and European ancestry proportions.

We predicted the natural log transformed urinary ratio of total 3HC/COT ($\text{uNMR}_{T/F}$, hereafter uNMR) in Pharmacogenetic Study participants using participant clinical and genotype data based on an ensemble model trained on Multiethnic Cohort (MEC) data³¹. In brief, the ensemble model was created using MEC participant age, gender, BMI, genomic ancestry and variants nominated from four genome-wide association scans of the NMR to train seven statistical models using measured MEC uNMR data³². The average of the seven models is the ensemble estimate.

For additional details, see **Supplementary Materials**.

Clinical Treatment Variables

Variables indicating source RCT^{27,28}, instructions to taper from NRT from weeks 8 to 12²⁷, and assignment of additional counseling sessions in weeks 10 and 12²⁷, were created to address variations in treatments across trials, and among participants in the last month before the 12 week assessment.

Imputation of Missing Data

Demographic and social categorical covariates were stratified (reference) for analysis: age (<50 years); gender (female); education (<college graduate); modified OMB race with African American, Multiple, Other (grouping four infrequent categories: Asian, Native American, Pacific Islander, and Other), and (White); OMB ethnicity (Non-Hispanic); and BMI (<25 kg/m²). Missing data were estimated using the missMDA R package with the `estim ncpFAMD` and `imputeFAMD` functions³³. Abstinence was assigned using the intent-to-treat (ITT) approach. All multivariate analyses were performed using the N=456 post-imputation dataset.

Statistical Analyses

We stratified participants by prospective abstinence and by covariates for descriptive analyses. We performed concurrent validity analysis of the predicted uNMR with linear regression with smoking measures as the outcomes. We used two covariate models in analysis. Covariate Model 1 included age, gender, education, OMB race, OMB ethnicity, and BMI, and Covariate Model 2 included age, gender, education, ancestry proportions and BMI. Predictive validity of smoking measures and uNMR with abstinence was assessed with logistic regression and the same covariate models. Descriptive analyses were performed in JMP (v. 15.0.0, SAS Institute Inc., Cary, NC, USA) and multivariate analyses in the R statistical language. The α level was .05 and tests of significance were two-sided.

RESULTS

Pharmacogenetic Study participant recruitment did not differ by RCT, and Pharmacogenetic Study participant demographic, social and smoking characteristics did not differ from RCT participant characteristics. See **Supplementary Table 1** for RCT and Pharmacogenetic Study recruitment numbers, **Supplementary Table 2** for comparison of RCT and Pharmacogenetic Study characteristics, and **Supplementary Materials** for details on RCT eligibility and interventions.

Univariate Analysis

Data missingness was low: demographic and social covariates, genomic variables, and smoking measure variable missingness rates were 0.0% - 2.0%, 4.0%, and 0.0% - 2.4%. Clinical variables were not associated with abstinence ($p\text{-values} \geq .50$), and were not included in further analyses. Education ($P=.096$), African American OMB race ($P=.012$), African ancestry ($P=.002$), CPD ($P=.007$), TTFC ($P=.003$), FTND score ($P=.010$) and the uNMR ($P=.052$) were significantly associated with abstinence (**Supplementary Table 3**). The directionality of education and NMR associations with abstinence are known, thus these associations were considered significant. All covariates except Hispanic ethnicity were significantly associated with CPD, FCPD and/or uNMR while gender and education were associated with the FTND (**Table 2**). There were no covariate associations with the CO or TTFC smoking measures. Participants who were younger, female, college-educated, minority OMB race or ethnicity, normal weight or with African ancestry or Asian ancestry were more likely to exhibit reduced smoking measure levels, while covariate relations with uNMR were mixed. See **Supplementary Table 4** for stratified covariates.

Concurrent Validity of the uNMR

The uNMR was significantly associated with CO in each covariate model (**Table 3**). Multiple covariates were significantly associated with the smoking measures CPD, FCPD and FTND (**Table 3**). In Covariate Model 1 (**Supplementary Table 5**), age, gender, education, and African American OMB race were associated with CPD, and age, gender, African American OMB race, Other OMB race and BMI were associated with FCPD. In Covariate Model 2 (**Supplementary Table 6**), age, gender, education, African ancestry and Asian ancestry were associated with CPD, and age, gender, African ancestry, Asian ancestry and BMI were associated with the FCPD; also, education and Asian ancestry were associated with FTND.

Predictive Validity Analyses

Four smoking-related measures exhibited association with abstinence (**Table 4**). Odds ratios (OR (95%CI) *P*) ranged from 0.56 (0.34-0.92) .023 and 0.58 (0.35-0.97) .039 for the uNMR in Covariate Models 1 and 2, to 0.95 (0.93-0.98) <.001 for CPD in both Covariate Models. Each individual smoking-related measure had essentially the same standardized effect estimate in both Covariate Models. African American OMB race (Covariate Model 1) and African ancestry (Covariate Model 2) were significantly ($P<.001$) associated with abstinence in all models, including the non-significant FCPD and CO models (**Supplementary Tables 7 and 8**). The reduced odds ratios of abstinence associated with African American OMB race and African ancestry were lower than the odds ratios associated with the CPD and FTND measures (Table 4). The odd ratios of abstinence associated with African ancestry were one-third lower than those associated with African American OMB race, but confidence intervals substantially overlapped. The other covariate associated with abstinence was BMI ($P=.048$) in the CPD model in Covariate Model 2.

DISCUSSION

This study is the first to relate prospective abstinence and several traditional smoking measures to a predicted measure of nicotine metabolism based on a novel ensemble model we have developed using genomic ancestry. This study is the first to compare the predictive utility of smoking measures in covariate models that differ by inclusion of the social construct of race and genomic measures of ancestry.

Validation of the predicted uNMR measure

From prior research in both population cohorts and treatment-seeking smokers of multiple ethnicities, with biochemical measures of the NMR and uNMR, and genetic models of the NMR or *CYP2A6* activity, we expected to observe associations between the predicted uNMR and gender, OMB race, BMI, measures of smoking intensity (but not the FTND), and abstinence^{13,34–37}. We observed expected associations of the uNMR with OMB race categories and BMI, and novel associations with African ancestry and Asian ancestry proportions in treatment seeking smokers. We observed in multivariate analyses that covariates were significantly associated with measures of smoking intensity (CPD and FCPD) and nicotine dependence (FTND), but not with predicted uNMR. The variables gender, OMB race, BMI and CPD have previously been associated with the NMR in treatment-seeking smokers with similar explained variance³⁵ to the associations observed with smoking intensity measures. We did not expect to observe association of the uNMR with CO as a larger sample of treatment-seeking smokers ($N=1700$, 35% African American) did not observe association of the NMR with CO²².

The uNMR abstinence association we observed is directionally consistent with previous NMR abstinence research³⁸, and has a similar effect size found in a meta-analysis of abstinence at six months in $N=718$ non-Hispanic Black and non-Hispanic White smokers randomized to active NRT comparing smokers with normal NMR to those with slow NMR (Relative Risk of 0.54 and

95%CI 0.37 to 0.78)³⁹. Larger samples are necessary to investigate more complex relations (interactions) between the predicted uNMR, covariates, smoking measures and treatment outcomes not tested in our planned analysis.

Smoking measures, OMB race and ancestry

African American smokers exhibit lower levels of most smoking intensity measures and nicotine biomarkers, except for higher levels of biomarkers of nicotine exposure per cigarette and higher levels of plasma COT; the mechanistic reasons for the first exception are not understood, while the second exception is due to increased NIC intake per cigarette, reduced NIC oxidative metabolism and to reduced NIC and COT glucuronidation^{21,40}. The associations we observed in the Pharmacogenetic Study between African American OMB race, decreased smoking intensity measures and predicted nicotine metabolism are consistent with prior studies. Multiple (self-identified OMB multiracial race category) and Other (an aggregated category of self-identified OMB Asian, Native American, Pacific Islander and Other race categories) OMB race categories were associated with reduced smoking intensity and nicotine metabolism measures in the Pharmacogenetic Study, although associations with smoking intensity moderated upon adjustment for nicotine metabolism in multivariate analysis. The reduced smoking measures seen in the aggregated Other category used in this analysis are consistent with reduced CPD and nicotine metabolism in Native Hawaiian and Japanese American smokers²³.

African ancestry and Asian ancestry were associated with decreased smoking intensity and nicotine metabolism measures in Pharmacogenetic Study participants. Ancestry within self-identified ethnic strata was examined for association with CPD in non-treatment seeking ever smokers from a health maintenance organization (mean(SD) 55(11) years of age and 58% female)⁴¹. Within group association of the first two geographically interpretable principal components of genetic variation was observed in non-Hispanic White ($N=12898$, 13% current),

in East Asian ($N=921$, 15% current), but not in African American ($N=554$, 24% current) ever smokers. However, this analysis differs from our analysis in stratifying by self-identified ethnicity before ancestry analysis and by analyzing ever smokers vs treatment-seeking current smokers.

OMB race and abstinence

Analyses of multiethnic randomized cessation trials have observed an approximately 50% reduction of prospective abstinence among African American smokers in the United States. Therefore, we expected to observe a significant reduction in abstinence in African American smokers in the Pharmacogenetic Study. The range of standardized effect estimates we observed, from ORs (95%CI) of 0.31 (0.14-0.69) in the CPD model to 0.34 (0.15-0.74) in the uNMR model, encompass estimates from studies with a variety of designs: randomized on gender and OMB race⁴², stratified by OMB race⁶, or stratified by psychiatric diagnosis⁸.

Ancestry and abstinence

One published study identified association of measured African genomic ancestry with prospective abstinence (7-day point prevalence at 4 weeks), using a novel genetic analysis of ancestry and secondary analysis of a cessation trial of naltrexone vs placebo where all participants also received NRT and counseling⁴³. Bress *et al* observed significantly increased abstinence rates in $N=136$ self-identified White, European ancestry participants randomized to naltrexone but this treatment effect was not observed in $N=95$ self-identified African American, African ancestry participants. Within the African American participants, treatment was associated with increased abstinence in those with <80% West African ancestry, while participants with $\geq 80\%$ West African ancestry did not report an effect of treatment. While the European and African ancestry treatment interaction was non-significant, the West African ancestry interaction ($P<.03$) suggested a potential influence of ancestry on response to naltrexone⁴³. The findings of Bress *et al* and our findings of African ancestry association with

abstinence are not exactly comparable due to differences in trial characteristics and analysis designs. The additional 10% reduction in the odds of abstinence associated with African ancestry compared to African American OMB race in the Pharmacogenetic Study suggests that African ancestry may convey additional reductions in abstinence. Future studies will need to assess potential confounding between ancestry and socioeconomic factors associated with reductions in abstinence in African Americans⁶, and potential moderation, e.g., by gender⁴⁴.

Translational Implications

Confirmation of the African American TRHD of reduced abstinence using both the social construct of race and genomic ancestry, and the novel association of the predicted uNMR with abstinence, supports future analyses of cessation trials of sufficient sample size to observe and dissect disparities by ancestry⁴⁵, models of nicotine metabolism and consumption^{25,46}, socioeconomic factors⁶, and treatments. Such combined biopsychosocial cessation research would support reenvisioning of interventions in the context of the public health crises in the United States⁴⁷.

Limitations

In this analysis we approached variable analysis in a conservative manner (pre-planned analyses and dichotomous stratification of most covariates), and future research might use alternative approaches. Socioeconomic or related covariates were limited to education or BMI. The most profound limitation was lack of information on use of mentholated cigarettes, subject to targeted marketing to African Americans, and associated with reduced quit ratios in African Americans⁴⁸. For detailed strengths and limitations, please see **Supplementary Materials**.

Back Matter

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Funding

This work was supported by the National Institute on Alcohol Abuse and Alcoholism (R44 AA027675 to JWB and AWB). The sponsor had no role in the analysis of data, writing of the report, or in the decision to submit the paper for publication.

Declaration of Interests

AWB is an employee of Oregon Research Institute and ORI Community and Evaluation Services, and serves as a Scientific Advisor and Consultant to BioRealm LLC. CME and JWB are members and employees of BioRealm LLC. JWB, CSM and AWB are co-inventors on a related patent application "Biosignature Discovery for Substance Use Disorder Using Statistical Learning", assigned to BioRealm, LLC. BioRealm LLC offers genotyping and data analysis services. Other authors declare that they have no competing interests.

Acknowledgements

We thank the participants, Principal Investigators, co-Investigators and staff of the RCTs and the Pharmacogenetic Study. The National Institute on Drug Abuse funded the RCTs (R01 DA02538, K05 DA016752, K23 DA018691, and P50 DA09253), and the Pharmacogenetic Study (U01 DA020830). We thank Denise Nishita, Lisa Jack and Gary Swan (site-PI), Pharmacogenetics of Nicotine Addiction Treatment Consortium at SRI International (U01 DA020830, MPI: NL Benowitz, RF Tyndale and C Lerman), for their essential contributions that enabled this study. We acknowledge the BioRealm LLC team for supporting project workflows and computation, and IBX for DNA sample processing.

References

1. US Surgeon General. *The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General*. (Centers for Disease Control and Prevention (US), 2014).
2. Institute, U. S. N. C. A socioecological approach to addressing tobacco-related health disparities. *National Cancer Institute Tobacco Control Monograph 22. NIH Publication No. 17-CA-8035A* (2017).
3. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. *The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General*. (Centers for Disease Control and Prevention (US), 2014).
4. Prochaska, J. J., Das, S. & Young-Wolff, K. C. Smoking, Mental Illness, and Public Health. *Annu. Rev. Public Health* **38**, 165–185 (2017).
5. Nollen, N. L. *et al.* A clinical trial to examine disparities in quitting between African-American and White adult smokers: Design, accrual, and baseline characteristics. *Contemp. Clin. Trials* **47**, 12–21 (2016).
6. Nollen, N. L. *et al.* Factors That Explain Differences in Abstinence Between Black and White Smokers: A Prospective Intervention Study. *J. Natl. Cancer Inst.* **111**, 1078–1087 (2019).
7. Kendzor, D. E. *et al.* Financial strain and smoking cessation among racially/ethnically diverse smokers. *Am. J. Public Health* **100**, 702–706 (2010).
8. Nollen, N. L. *et al.* Assessment of Racial Differences in Pharmacotherapy Efficacy for Smoking Cessation: Secondary Analysis of the EAGLES Randomized Clinical Trial. *JAMA Netw Open* **4**, e2032053 (2021).
9. Anthenelli, R. M. *et al.* Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. *Lancet* **387**, 2507–2520 (2016).
10. Dempsey, D. *et al.* Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic

- activity. *Clin. Pharmacol. Ther.* **76**, 64–72 (2004).
11. Benowitz, N. L., St Helen, G., Nardone, N., Cox, L. S. & Jacob, P. Urine Metabolites for Estimating Daily Intake of Nicotine From Cigarette Smoking. *Nicotine Tob. Res.* **22**, 288–292 (2020).
 12. Benowitz, N. L., Pomerleau, O. F., Pomerleau, C. S. & Jacob, P., 3rd. Nicotine metabolite ratio as a predictor of cigarette consumption. *Nicotine Tob. Res.* **5**, 621–624 (2003).
 13. West, O., Hajek, P. & McRobbie, H. Systematic review of the relationship between the 3-hydroxycotinine/cotinine ratio and cigarette dependence. *Psychopharmacology* **218**, 313–322 (2011).
 14. Muhammad-Kah, R. S., Hayden, A. D., Liang, Q., Frost-Pineda, K. & Sarkar, M. The relationship between nicotine dependence scores and biomarkers of exposure in adult cigarette smokers. *Regul. Toxicol. Pharmacol.* **60**, 79–83 (2011).
 15. Bierut, L. J. *et al.* Variants in nicotinic receptors and risk for nicotine dependence. *Am. J. Psychiatry* **165**, 1163–1171 (2008).
 16. Chen, L.-S. *et al.* Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNA4) and cessation treatments in smoking cessation success. *Am. J. Psychiatry* **169**, 735–742 (2012).
 17. Chen, L.-S. *et al.* Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-Analysis. *EBioMedicine* **11**, 219–226 (2016).
 18. Bierut, L. J. & Tyndale, R. F. Preparing the Way: Exploiting Genomic Medicine to Stop Smoking. *Trends Mol. Med.* **24**, 187–196 (2018).
 19. Lerman, C. *et al.* Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. *Lancet Respir Med* **3**, 131–138 (2015).
 20. Chen, L.-S. *et al.* Genetic Variant in CHRNA5 and Response to Varenicline and

Combination Nicotine Replacement in a randomized placebo-controlled trial. *Clin.*

Pharmacol. Ther. (2020) doi:10.1002/cpt.1971.

21. Pérez-Stable, E. J., Herrera, B., Jacob, P., 3rd & Benowitz, N. L. Nicotine metabolism and intake in black and white smokers. *JAMA* **280**, 152–156 (1998).
22. Ross, K. C. *et al.* Racial differences in the relationship between rate of nicotine metabolism and nicotine intake from cigarette smoking. *Pharmacol. Biochem. Behav.* **148**, 1–7 (2016).
23. Patel, Y. M. *et al.* Novel Association of Genetic Markers Affecting CYP2A6 Activity and Lung Cancer Risk. *Cancer Res.* **76**, 5768–5776 (2016).
24. Benowitz, N. L., Dains, K. M., Dempsey, D., Wilson, M. & Jacob, P. Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure. *Nicotine Tob. Res.* **13**, 772–783 (2011).
25. Stram, D. O. *et al.* Racial/Ethnic Differences in Lung Cancer Incidence in the Multiethnic Cohort Study: An Update. *J. Natl. Cancer Inst.* **111**, 811–819 (2019).
26. St Helen, G. *et al.* Differences in exposure to toxic and/or carcinogenic volatile organic compounds between Black and White cigarette smokers. *J. Expo. Sci. Environ. Epidemiol.* (2019) doi:10.1038/s41370-019-0159-9.
27. Hall, S. M. *et al.* Extended treatment of older cigarette smokers. *Addiction* **104**, 1043–1052 (2009).
28. Hall, S. M. *et al.* Using extended cognitive behavioral treatment and medication to treat dependent smokers. *Am. J. Public Health* **101**, 2349–2356 (2011).
29. Bergen, A. W. *et al.* Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption. *PLoS One* **10**, e0126113 (2015).
30. Raj, A., Stephens, M. & Pritchard, J. K. fastSTRUCTURE: variational inference of population structure in large SNP data sets. *Genetics* **197**, 573–589 (2014).
31. Murphy, S. E. *et al.* Nicotine N-glucuronidation relative to N-oxidation and C-oxidation and

- UGT2B10 genotype in five ethnic/racial groups. *Carcinogenesis* **35**, 2526–2533 (2014).
32. Baurley, J. W. *et al.* Predicting Nicotine Metabolism Across Ancestries Using Genotypes. *Medrxiv.org* (2021).
33. Audigier, V., Husson, F. & Josse, J. A principal component method to impute missing values for mixed data. *Adv. Data Anal. Classif.* **10**, 5–26 (2016).
34. Bloom, A. J. *et al.* Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6. *Hum. Mol. Genet.* **21**, 3050–3062 (2012).
35. Chenoweth, M. J. *et al.* Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers. *Cancer Epidemiol. Biomarkers Prev.* **23**, 1773–1782 (2014).
36. Chen, L.-S. *et al.* Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). *Addiction* **109**, 128–137 (2014).
37. El-Boraie, A. *et al.* Transferability Of Ancestry-Specific And Cross-Ancestry CYP2A6 Activity Genetic Risk Scores In African And European Populations. *Clin. Pharmacol. Ther.* (2020) doi:10.1002/cpt.2135.
38. Siegel, S. D., Lerman, C., Flitter, A. & Schnoll, R. A. The Use of the Nicotine Metabolite Ratio as a Biomarker to Personalize Smoking Cessation Treatment: Current Evidence and Future Directions. *Cancer Prev. Res.* **13**, 261–272 (2020).
39. Schuit, E. *et al.* Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. *Cochrane Database Syst. Rev.* **9**, CD011823 (2017).
40. Benowitz, N. L. *et al.* Ethnic differences in N-glucuronidation of nicotine and cotinine. *J. Pharmacol. Exp. Ther.* **291**, 1196–1203 (1999).
41. Choquet, H., Yin, J. & Jorgenson, E. Cigarette smoking behaviors and the importance of ethnicity and genetic ancestry. *Transl. Psychiatry* **11**, 120 (2021).
42. Piper, M. E. *et al.* Gender, race, and education differences in abstinence rates among

participants in two randomized smoking cessation trials. *Nicotine Tob. Res.* **12**, 647–657 (2010).

43. Bress, A., Kittles, R., Wing, C., Hooker, S. E., Jr & King, A. Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: an analysis of a randomized controlled trial. *Pharmacogenet. Genomics* **25**, 305–312 (2015).
44. Alexander, A. C. *et al.* Darker skin color is associated with a lower likelihood of smoking cessation among males but not females. *Soc. Sci. Med.* **240**, 112562 (2019).
45. Bray, M. J. *et al.* Studying the utility of using genetics to predict smoking-related outcomes in a population-based study and a selected cohort. *Nicotine Tob. Res.* (2021) doi:10.1093/ntr/ntab100.
46. Bergen, A. W. *et al.* Multiethnic Prediction of Nicotine Biomarkers and Association With Nicotine Dependence. *Nicotine Tob. Res.* (2021) doi:10.1093/ntr/ntab124.
47. Beech, B. M., Ford, C., Thorpe, R. J., Jr, Bruce, M. A. & Norris, K. C. Poverty, Racism, and the Public Health Crisis in America. *Front Public Health* **9**, 699049 (2021).
48. Smith, P. H. *et al.* Use of Mentholated Cigarettes and Likelihood of Smoking Cessation in the United States: A Meta-Analysis. *Nicotine Tob. Res.* **22**, 307–316 (2020).

TABLES

Table 1: Pharmacogenetic Study Participant Characteristics, N=456

Characteristic	Definition	Type	N (%) or M (SD)
RCT Source	NCT00087880	Clinical	220 (48.2%)
Taper	Taper NRT	Clinical	112 (24.6%)
Session	7 Sessions	Clinical	96 (21.1%)
Age	<50 years	Demographic	187 (41.0%)
Gender	Female	Demographic	189 (41.5%)
Education	<College graduate	Social	224 (49.3%)
African American	Self-identified	Social	33 (7.4%)
Multiple	Self-identified	Social	42 (9.4%)
Other	Aggregated*	Social	29 (6.5%)
White	Self-identified	Social	343 (76.7%)
Hispanic	OMB Ethnicity	Social	30 (6.7%)
BMI <25 kg/m ²	Adiposity	Clinical	203 (45.7%)
African Ancestry	Continuous	Genomic	0.098 (0.265)
Asian Ancestry	Continuous	Genomic	0.076 (0.224)
CO (ppm)	Carbon monoxide	Smoking	20.9 (10.8)
CPD	Cigarettes per Day	Smoking	19.4 (7.7)
FTND (0-10)	Fagerström Test**	Smoking	4.76 (2.1)
TTFC (0-3)	Time-To-First-Cigarette	Smoking	1.84 (0.98)
FCPD (0-3)	Fagerström CPD	Smoking	1.44 (0.68)
uNMR	Predicted uNMR	Genomic	1.22 (0.43)
Abstinent	Completor only	Clinical	265/429 (61.8%)
Abstinent (ITT)	By ITT method	Clinical	265/456 (58.1%)

*Modified Other (Asian, Native American, Other, Pacific Islander). **for Nicotine Dependence.

Table 2: Sociodemographics, Smoking Measures and uNMR

		CO	CPD	FTND	TTFC	FCPD	uNMR
Age	<i>t</i>	1.05	3.28	0.313	1.54	3.29	1.30
	<i>P</i>	.293	.001	.754	.125	.001	.195
Gender	<i>t</i>	-1.28	-4.12	-2.04	-1.11	-2.74	1.53
	<i>P</i>	.201	<.001	.042	.269	.006	.127
Education	<i>t</i>	-1.23	-1.93	-2.15	-1.72	-0.255	1.15
	<i>P</i>	.221	.055	.032	.087	.799	.249
African American	<i>t</i>	-0.11	-2.45	-0.87	-0.59	-2.18	-2.58
	<i>P</i>	.914	.015	.39	.557	.030	.010
Multiple	<i>t</i>	-1.04	-1.63	-1.27	-1.08	-2.20	-4.71
	<i>P</i>	.299	.103	.205	.281	.029	<.001
Other	<i>t</i>	-1.16	-2.18	-0.92	-0.10	-2.80	-5.79
	<i>P</i>	.247	.030	.359	.923	0.005	<.001
Hispanic	<i>t</i>	1.06	0.142	1.28	0.724	0.726	-0.317
	<i>P</i>	.290	.887	.202	.469	.468	.751
BMI	<i>t</i>	0.03	1.74	1.29	0.763	1.87	-2.62
	<i>P</i>	.979	.083	.199	.446	.063	.009
African ancestry	<i>t</i>	-0.58	-2.27	-0.296	0.675	-2.06	-2.73
	<i>P</i>	.561	.024	.767	.500	.040	.007
Asian ancestry	<i>t</i>	-0.82	-2.74	-1.89	-1.54	-3.34	-8.17
	<i>P</i>	.412	.006	.060	.124	<.001	<.001

Covariates are predictors (reference for categorical variables) and smoking measures are outcomes: Age (<50 years); Gender (Male); Education (<College graduate); OMB Race, African American, Multiple, Other and (White); OMB Ethnicity (Hispanic); BMI (<25) kg/m²), African ancestry, Asian ancestry. Smoking Measures: CO (ppm), CPD=Cigarettes per day (continuous), FTND=FTND Total, TTFC=FTND Time-To-First-Cigarette item, FCPD=FTND CPD item. uNMR=Predicted natural log uNMR.

Table 3: uNMR and Smoking Measures

	β	SE	<i>P</i>	r^2	adj. r^2	<i>F P-value</i>
Covariate Model 1						
CO	3.80	1.29	.003	0.035	0.015	.070
CPD	1.39	0.89	.120	0.099	0.081	<.001
FTCD	0.18	0.25	.469	0.035	0.016	.063
TTFC	0.10	0.12	.400	0.023	0.003	.317
FCPD	0.07	0.08	.390	0.084	0.066	<.001
Covariate Model 2						
CO	3.88	1.32	.004	0.032	0.017	.044
CPD	0.82	0.90	.364	0.110	0.096	<.001
FTCD	0.06	0.25	.830	0.036	0.021	.022
TTFC	0.07	0.12	.585	0.023	0.008	.163
FCPD	0.02	0.08	.815	0.096	0.082	<.001

The uNMR is the predictor and smoking measures are the outcomes. Covariate Model 1 adjusted for age, gender, education, OMB race and ethnicity, and BMI. Covariate Model 2 adjusted for age, gender, education, ancestry proportions, and BMI.

Table 4: Smoking, OMB Race, Ancestry and Abstinence

	β	SE	P	OR	LCI - UCI
Covariate Model 1					
CO	-0.01	0.01	0.193	0.99	0.97 - 1.01
African American	-0.98	0.40	0.013	0.37	0.17 - 0.81
CPD	-0.05	0.01	<0.001	0.95	0.93 - 0.98
African American	-1.16	0.40	0.004	0.31	0.14 - 0.69
FTND	-0.12	0.05	0.012	0.89	0.81 - 0.97
African American	-1.05	0.40	0.008	0.35	0.16 - 0.76
TTFC	-0.31	0.10	0.003	0.73	0.60 - 0.90
African American	-1.05	0.40	0.009	0.35	0.16 - 0.77
FCPD	-0.29	0.15	0.057	0.75	0.56 - 1.01
African American	-1.07	0.40	0.007	0.34	0.16 - 0.75
uNMR	-0.58	0.25	0.023	0.56	0.34 - 0.92
African American	-1.08	0.40	0.007	0.34	0.15 - 0.74
Covariate Model 2					
CO	-0.01	0.01	0.171	0.99	0.97 - 1.01
African ancestry	-1.36	0.46	0.003	0.26	0.10 - 0.64
CPD	-0.05	0.01	<0.001	0.95	0.93 - 0.98
African ancestry	-1.57	0.47	<0.001	0.21	0.08 - 0.53
FTND	-0.12	0.05	0.014	0.89	0.81 - 0.98
African ancestry	-1.41	0.47	0.003	0.24	0.10 - 0.61
TTFC	-0.29	0.10	0.005	0.75	0.61 - 0.92
African ancestry	-1.35	0.47	0.004	0.26	0.10 - 0.65
FCPD	-0.28	0.15	0.063	0.75	0.56 - 1.02
African ancestry	-1.46	0.47	0.002	0.23	0.09 - 0.58
uNMR	-0.54	0.26	0.039	0.58	0.35 - 0.97
African ancestry	-1.49	0.47	0.002	0.22	0.09 - 0.57

Smoking measures are predictors and abstinence is the outcome. Covariate Model 1 adjusted for age, gender, education, OMB race and ethnicity, and BMI. Covariate Model 2 adjusted for age, gender, education, ancestry proportions, and BMI.